Fangsheng Pharmaceutical announced that the holding subsidiary, Xiangya Pharmaceutical, plans to use its own capital of 9.8 million yuan to transfer 70% of the pre-clinical trial technology and results of the “Sanhua Dissolved Granules” held by the related party Fangsheng Rongke, and promote subsequent research and development through cooperative research and development. The transaction constitutes a related transaction. It has been reviewed and approved by the company's board of directors, and there is no need to submit it to the shareholders' meeting for review; “Sanhua Qinghai Granules” obtained the “Pharmaceutical Clinical Trial Approval Notice” in August 2026.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.